David Planchard: Some advances for our BRAF V600E NSCLC patients…Review to read at npj Journals

David Planchard, Professor at the University of Paris-Saclay, posted on X/Twitter:

“Some advances for our BRAF V600E NSCLC patients… two standards in 2024 with Dabrafenib + Trametinib and Encorafenib + Binimetinib.
Review to read at npj Journals.”

Source: David Planchard/X

About OncoDaily 

OncoDaily was founded in 2023. It is a US-based oncology media platform, which features the latest news, insights, and patient stories from the world of oncology. Within a short period of time it became one of the leading oncology media platforms globally.

OncoDaily gathers content from various sources, including social media posts from renowned oncologists from all over the world, news from oncology societies and cancer centers, patient and survivor stories, and career-related information for professionals.

The mission of OncoDaily is to empower patients, survivors, and professionals with the knowledge and inspiration they need to fight cancer. The motto of OncoDaily is “Cancer doesn’t take a day off – neither do we”.